On Friday, the FDA accepted and granted Priority Review AstraZeneca Plc’s (NASDAQ:AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) for patients with muscle-invasive bladder cancer (MIBC). The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2025. The supplement application is based on data […]
Sales Force: These Analysts Boost Their Forecasts
Salesforce Inc. (NYSE:CRM) posted downbeat earnings for its third quarter, while sales topped estimates. Salesforce reported third-quarter revenue of $9.44 billion, beating the consensus estimate of $9.35 billion. The enterprise cloud solutions company reported adjusted earnings of $2.41 per share, missing analyst estimates of $2.44 per share, according to Benzinga Pro. “We delivered another quarter […]
Tesla Registrations Tumble 64% In UK In October Even As Overall EV Registrations Rise
EV giant Tesla Inc.’s (NASDAQ:TSLA) car registrations dropped by a steep 64% in October as compared to the corresponding period last year, according to industry data. What Happened: Tesla had just 971 new vehicle registrations in October as compared to 2,677 in October 2023, the Society of Motor Manufacturers and Traders (SMMT) said. This is […]
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush analyst Daniel Ives upgraded the rating for Snowflake Inc. (NYSE:SNOW) from Neutral to Outperform and announced a $190 price target. Snowflake shares closed at […]
Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said MicroStrategy Incorporated (NASDAQ:MSTR) is a Bitcoin play and he prefers to actually own Bitcoin (CRYPTO: BTC). MicroStrategy announced it completed its previously announced offering of its 0% convertible senior notes due 2029. MicroStrategy said the aggregate principal amount of the notes sold in the offering was […]
Top 3 Risk Off Stocks That May Collapse This Quarter
As of Nov. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices […]
Coinbase CEO: DOGE Department Is A ‘Once-In-A-Lifetime-Opprtunity,’ Abolishing Individual Income Tax
Coinbase CEO Brian Armstrong has proposed eliminating individual income taxes in the U.S., suggesting a radical shift in the tax burden to businesses and alternative revenue sources like sales taxes. What Happened: Armstrong’s call, shared in a series of tweets on Sunday, aligns with his broader vision for reducing government size and enhancing economic freedom. […]
What’s Going On With Kraft Heinz Stock Today?
Kraft Heinz (NASDAQ:KHC) shares remained relatively flat in premarket trading on Friday following a legal setback and the discontinuation of its reworked Lunchables meals for U.S. schools. A federal judge recently ruled that Kraft Heinz must face a proposed nationwide class action lawsuit over its Kraft Mac & Cheese product, Reuters reports. The lawsuit, filed […]
Newsletter
AstraZeneca’s Imfinzi Goes Under FDA Priority Review For Bladder Cancer
December 6, 2024
On Friday, the FDA accepted and granted Priority Review AstraZeneca Plc’s (NASDAQ:AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) for patients with muscle-invasive bladder cancer (MIBC). The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2025. The supplement application is based on data […]
Read More